Olaris Adds Strategic Investment from Bruker Corporation
“Olaris has developed a powerful platform for discovering actionable metabolomic biomarkers,” said Dr. Falko Busse, the President of the Bruker BioSpin Group. “We are excited to support their vision and collaborate on driving new applications of metabolomics in precision health.” Post this “We are thrilled to have Bruker as a strategic investor and partner,” said … Read more